Liver Int:FABP4,通常在肝脏中不表达的FABP,可以由肝细胞和HCC细胞合成和分泌,可能会调节肿瘤进展

2018-06-06 MedSci MedSci原创

研究表明FABP4,一种在肝脏中通常不表达的FABP,可以由肝细胞和HCC细胞合成和分泌;并且在肥胖背景下,FABP4可能调节肿瘤进展。

研究背景:肝细胞癌(HCC)是癌症死亡的第三大病因。肝癌的危险因素包括病毒性肝炎、酒精和肥胖。脂肪酸结合蛋白(FABPs)结合长链游离脂肪酸(FFAs),以组织特异性的模式表达;FABP1主要在肝脏中表达,而FABP4主要在脂肪细胞中表达。本研究旨在探讨FABP1 -9在肥胖相关HCC的人和动物模型中的表达及功能。

研究方法:在肥胖导致的HCC小鼠模型中,检测了FABP1-9的表达。基于这些数据,检测体外培养的人肝癌细胞(HepG2和HuH7)中FABP4的表达和功能。在患者的血清中检测循环的FABP4水平。

研究结果:研究表明,独立与肿瘤状态,肥胖小鼠肝脏的FABP4 mRNA和蛋白水平增加,同时伴随着血清FABP4水平的增加。在体外,使用FFA诱导人肿瘤细胞FABP4的表达,导致FABP4被分泌到培养基。采用外源性的FABP4处理HCC细胞,结果显著增加了人HCC细胞的增殖和迁移能力。患者血清分析表明潜在肝病患者,尤其是非酒精性脂肪肝(NAFLD)和HCC患者的FABP4水平显著增加。

研究结论:研究表明FABP4,一种在肝脏中通常不表达的FABP,可以由肝细胞和HCC细胞合成和分泌;并且在肥胖背景下,FABP4可能调节肿瘤进展。

原始出处:

Thompson KJ, Austin RG, Nazari SS, et al. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int, 2018, 38(6), 1074-1083.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-10-13 wleon8895
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2019-01-10 gwc392
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2019-03-04 xjy02
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-08 jiyangfei
  6. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-07 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-07 131****1460

    学习了受益匪浅

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2049828, encodeId=159020498285d, content=<a href='/topic/show?id=4a5f1e68a9' target=_blank style='color:#2F92EE;'>#ABP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1768, encryptionId=4a5f1e68a9, topicName=ABP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Sat Oct 13 05:30:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682438, encodeId=f19516824386a, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Thu Jan 10 08:30:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863369, encodeId=b1801863369d2, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 04 09:30:00 CST 2019, time=2019-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737205, encodeId=df8c1e3720530, content=<a href='/topic/show?id=611e8312358' target=_blank style='color:#2F92EE;'>#肿瘤进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83123, encryptionId=611e8312358, topicName=肿瘤进展)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c47234265932, createdName=ms8435843352634314, createdTime=Sun Jun 10 22:30:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259504, encodeId=a0171259504d8, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Jun 08 13:30:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322167, encodeId=426832216ed9, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Jun 07 07:06:28 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322120, encodeId=de58322120d9, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jun 07 06:35:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322045, encodeId=0967322045e3, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jun 06 22:47:05 CST 2018, time=2018-06-06, status=1, ipAttribution=)]
    2018-06-06 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

相关资讯

Diabetes Care:FABP4预测1型糖尿病女性的子痫前期风险

子痫前期指怀孕前血压正常的孕妇在妊娠20周以后出现高血压、蛋白尿,又称为先兆子痫。是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。 脂肪酸结合蛋白4(FABP4)是胞内脂质结合蛋白超家族成员,在长链脂肪酸的摄取、转运及代谢调节中发挥重要作用,并涉及生物体的其他生命过程。 研究者对1型糖尿病女性患者进行了研究,探究FABP4和子痫前期风险之间的关系。 研究纳入了糖

Stroke:循环脂肪酸结合蛋白4是急性缺血性脑卒中患者一种新的预后生物标志物

上述数据表明FABP4是一个新的独立的预后指标,可以改善当前使用的脑卒中患者的危险分层。